Literature DB >> 11907097

Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.

Maria L Olleros1, Reto Guler, Nadia Corazza, Dominique Vesin, Hans-Pietro Eugster, Gilles Marchal, Pierre Chavarot, Christoph Mueller, Irene Garcia.   

Abstract

The contribution of a transmembrane (Tm) form of TNF to protective immunity against Mycobacterium bovis bacillus Calmette-Guérin (BCG) was studied in transgenic (tg) mice expressing a noncleavable Tm TNF but lacking the TNF/lymphotoxin-alpha (LT-alpha) locus (Tm TNF tg mice). These mice were as resistant to BCG infection as wild-type mice, whereas TNF/LT-alpha(-/-), TNF(-/-), and LT-alpha(-/-) mice succumbed. Tm TNF tg mice developed granulomas of smaller size but at 2- to 4-fold increased frequencies compared with wild-type mice. Granulomas were mainly formed by monocytes and activated macrophages expressing Tm TNF mRNA and accumulating acid phosphatase. NO synthase 2 activation as a key macrophage bactericidal mechanism was low during the acute phase of infection in Tm TNF tg mice but was still sufficient to limit bacterial growth and increased in late infection. While infection with virulent Mycobacterium tuberculosis resulted in very rapid death of TNF/LT-alpha(-/-) mice, it also resulted in survival of Tm TNF tg mice which presented an increase in the number of CFU in spleen (5-fold) and lungs (10-fold) as compared with bacterial load of wild-type mice. In conclusion, the Tm form of TNF induces an efficient cell-mediated immunity and total resistance against BCG even in the absence of LT-alpha and secreted TNF. However, Tm TNF-mediated protection against virulent M. tuberculosis infection can also be efficient but not as strong as in BCG infection, in which cognate cellular interactions may play a more predominant role in providing long-term surveillance and containment of BCG-infected macrophages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907097     DOI: 10.4049/jimmunol.168.7.3394

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

Review 1.  Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.

Authors:  Thomas W Spahn; Hans-Pietro Eugster; Adriano Fontana; Wolfram Domschke; Torsten Kucharzik
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

2.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Authors:  F Tubach; D Salmon; P Ravaud; Y Allanore; P Goupille; M Bréban; B Pallot-Prades; S Pouplin; A Sacchi; R M Chichemanian; S Bretagne; D Emilie; M Lemann; O Lortholary; O Lorthololary; X Mariette
Journal:  Arthritis Rheum       Date:  2009-07

3.  Transmembrane tumor necrosis factor alpha is required for enteropathy and is sufficient to promote parasite expulsion in gastrointestinal helminth infection.

Authors:  M X Ierna; H E Scales; C Mueller; C E Lawrence
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

4.  Soluble TNFRp75 regulates host protective immunity against Mycobacterium tuberculosis.

Authors:  Roanne Keeton; Nasiema Allie; Ivy Dambuza; Brian Abel; Nai-Jen Hsu; Boipelo Sebesho; Philippa Randall; Patricia Burger; Elizabeth Fick; Valerie F J Quesniaux; Bernhard Ryffel; Muazzam Jacobs
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

5.  Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections.

Authors:  Maria L Olleros; Reto Guler; Dominique Vesin; Roumen Parapanov; Gilles Marchal; Eduardo Martinez-Soria; Nadia Corazza; Jean-Claude Pache; Christoph Mueller; Irene Garcia
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

6.  Differential effects of total and partial neutralization of tumor necrosis factor on cell-mediated immunity to Mycobacterium bovis BCG infection.

Authors:  Reto Guler; Maria L Olleros; Dominique Vesin; Roumen Parapanov; Irene Garcia
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

7.  Soluble, but not transmembrane, TNF-α is required during influenza infection to limit the magnitude of immune responses and the extent of immunopathology.

Authors:  Matthew P DeBerge; Kenneth H Ely; Richard I Enelow
Journal:  J Immunol       Date:  2014-04-30       Impact factor: 5.422

Review 8.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

9.  T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection.

Authors:  B M Saunders; H Briscoe; W J Britton
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  Protective role of membrane tumour necrosis factor in the host's resistance to mycobacterial infection.

Authors:  Nasiema Allie; Lena Alexopoulou; Valerie J F Quesniaux; Lizette Fick; Ksanthi Kranidioti; George Kollias; Bernhard Ryffel; Muazzam Jacobs
Journal:  Immunology       Date:  2008-06-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.